WT1 and acute myeloid leukemia: A Phase 2 study investigated the effects of vaccinating 30 patients with Acute Myeloid Leukemia and at very high risk of relapse, using DCs electroporated with Wilms’ tumor 1 (WT1) mRNA as a post-remission treatment.